Video

Q&A With Pers Sorensen From Copenhagen University: ECTRIMS Grows As Treatment Options For Multiple Sclerosis Expands

Author(s):

In 1992 the European Committee For Treatment And Research in Multiple Sclerosis met in Barcelona with 200 people in attendance. Twenty three years later the same conference was held in the same city with more than 9000 people in attendance and more than 1000 abstracts submitted.

In 1992 the European Committee For Treatment And Research in Multiple Sclerosis (ECTRIMS) met in Barcelona with 200 people in attendance. Twenty three years later the same conference was held in the same city with more than 9000 people in attendance and more than 1000 abstracts submitted.

Pers Sorenson, MD, DMSc, from Copenhagen University Hospital, who also serves as Secretary General for ECTRIMS discussed how the conference has grown during the most recent meeting in the Spanish city.

Treatment for the relapsing remitting form of multiple sclerosis has improved by leaps and bounds over the past few years and there are signs of progress for the primary progressive form as well. Even while improvements have been made there is still much more work to be done in the field.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.